Scholar Rock Holding Corp (SRRK)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $40.52
- As of
Kresmion compiles this page from SRRK's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Scholar Rock Holding Corp (SRRK): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-15.
See the full SRRK dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for SRRK on one page. Preview it with sample data, then open it live with a free account.
Preview the SRRK dossierActive signals for SRRK
- highCONSENSUS_SELL
4 tracked funds reduced SRRK this 2026Q2, institutional consensus
- highCONSENSUS_BUY
3 tracked funds increased SRRK this 2026Q2, institutional consensus
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +137% to SRRK (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +677% to SRRK (2026Q2)
- mediumNEW_POSITION
RENAISSANCE TECHNOLOGIES LLC new position in SRRK
FREE, NO ACCOUNT
Every signal on SRRK, as it fires
You are seeing 5 of 9 signals recorded on SRRK since 2026-05-29.
The five above landed across 2 days. The other 4 were recorded on 1 other days. 5 of the 9 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in SRRK (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 80706P103 · 2026Q2 | $18.3M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 80706P103 · 2026Q2 | $13.5M | 0.01% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 80706P103 · 2026Q2 | $5M | 0.01% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 80706P103 · 2026Q2 | $994K | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 80706P103 · 2026Q2 | $525K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, SRRK
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
SRRK against its peers
SRRK's return on equity of -154.0% ranks in the 2nd percentile of 23 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-03-31.
| Metric | SRRK | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 0.0 USD | 227M USD | 3 | 16 |
| Operating margin | n/a | -127.1% | n/a | 16 |
| Net margin | n/a | -126.0% | n/a | 16 |
| Return on equity | -154.0% | -30.3% | 2 | 23 |
| 1 year | 18.2% | 98.5% | 21 | 20 |
Peers (25): CRSP, APLS, DFTX, TVTX, COGT, PTCT, ORKA, MANE, MIRM, ERAS, CGON, DNTH, LGND, BLTE, EWTX, GRAL, RYTM, CNTA, IMVT, KOD, TNGX, IOVA, RLAY, ALKS, CPRX. Fiscal periods ending between 2025-12-31 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (SRRK: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow SRRK on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to SRRK for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.